Overview

Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, dose escalation Phase 1 study.
Phase:
Phase 1
Details
Lead Sponsor:
Tragara Pharmaceuticals, Inc.
Treatments:
BB 1101
Citric Acid
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate